The benefits of PrEP is winning over support from international bodies and an increasing number of national governments. PrEP introduction is advancing on several fronts, but all this momentum has yet to impact some of the people who need it most, in particular, adolescent girls and young women with high risk of acquiring HIV. Check out our up-close look at the issue from AVAC 2016’s Big Data, Real People.
Programs but Not Yet Platforms: The peril and promise of women’s biomedical HIV prevention in 2016
After FACTS: What’s next for HIV prevention in women?
FACTS 001, which released data at CROI, found no evidence of protection overall associated with the vaginal gel. Partners Demonstration Project, which reported data at the same meeting, found that serodiscordant couples using oral PrEP and/or ART had very low levels of HIV transmission. In this webinar, we discussed what these and other data meant for women, including young and adolescent girls.
Data and Uncertainty: Understanding updates on hormonal contraceptives and HIV
AIDS 2014 featured analyses of data on the potential relationship between hormonal contraceptives and risk of HIV infection. Researchers Charles Morrison (FHI 360) and Kristin Wall (Emory University), and Mary Lyn Gaffield from the WHO discussed the newest findings and guidance.
Creating a Prevention Agenda for Women: AVAC/CHANGE meeting for coordinated global advocacy
This report, released by CHANGE and cosponsored by AVAC, summarizes the key recommendations related to integration of HIV and family planning services, how to best move forward in the context of uncertainty about whether some hormonal contraceptives (HC) increase HIV risk, and how to advance “method mix”—a wider array of contraceptive choices for women everywhere.
Facing Questions about Hormonal Contraceptives and HIV: What’s next in getting answers?
In this webinar we learned about and discussed proposed research to directly evaluate how different family planning methods might impact HIV risk.
Trial designs are actively being discussed and funding is being sought for such research—but there are many questions where advocates’ voices are needed: What should a trial look like? How can method mix (the range of available family planning options) be expanded for all women? What can be done to better integrate HIV and family planning in the meantime?
View the full webinar here
Multipurpose Prevention Technologies (MPTs): An introductory factsheet
This introductory 2-page document makes the case for why women need prevention options that protect them against multiple risks—HIV, STIs and/or pregnancy—and discusses the products that are being studied for this purpose. The factsheet is part of a series on emerging HIV prevention strategies.
Microbicides for HIV Prevention: An introductory factsheet
This introductory 2-page document defines microbicides and reviews the state of research on some leading candidates.
Women and HIV Prevention Research: Designing, testing and marketing products to improve adherence
The fourth webinar in AVAC’s Research & Reality series, a year-long dialogue about prevention research and advocacy, this webinar provided a forum to learn about and discuss key issues around women and the HIV prevention agenda, including challenges around marketing of and adherence to new prevention options. Click for speaker details, slides and audio.
Report of Community Consultation Among Young Women Living with HIV Currently Accessing PMTCT Services in Benue, Edo, Akwa-Ibom and Lagos States
A 7-page document developed by 2013 AVAC Fellow Oladayo Taiwo Oyelakin identifying challenges women face in access PMTCT services in Nigeria. This report used a community community consultation framework to identify barriers and provide recommendations.
MPT Product Development & Regulatory Issues 101
This webinar featured experts Dr. Joe Romano (NWJ Group/CAMI) and Dr. Jim Turpin (NIAID) who provided updates on the state of multipurpose prevention technologies (MPTs) research, the pipeline and potential manufacturing and regulatory pathways. MPTs are being developed to simultaneously prevent unintended pregnancy and protect against HIV and other sexually transmitted infections.Click to access the webinar slides and recording.